Huang Y, et al. - Researchers sought to assess the utility of EPIC in addition to hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal adenocarcinoma with peritoneal dissemination. They realized the potential of the combination of HIPEC and EPIC in providing additional survival benefit for patients with PMCA with peritoneal spread as compared to HIPEC alone without increasing postoperative morbidity and mortality. To further confirm the potential benefits of EPIC in PMCA and address the question of optimal drug and/or duration of EPIC, further studies were recommended.